GlassScriptPhysician profile
Sandra K Kelley
NPI 1699519660
$1,840.53
in general payments reported to CMS, 2019-2025
32 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $371 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.54 |
| Education | $191.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $287.75 | 2024-2025 | Erleada, Rybrevant, Balversa |
| Incyte Corporation | $181.21 | 2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $124.11 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $120.07 | 2024-2025 | Tagrisso, Calquence, Enhertu |
| Celgene Corporation | $105.87 | 2024-2025 | Reblozyl |
| Genentech USA, INC. | $98.72 | 2025 | Venclexta, Polivy, Lunsumio |
| Ipsen Biopharmaceuticals, INC | $92.98 | 2024-2025 | Onivyde |
| Genzyme Corporation | $79.01 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.23 | 2024-2025 | Ninlaro, Alunbrig |
| Merck Sharp & Dohme LLC | $52.27 | 2024-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $50.75 | 2025 | Enhertu |
| Deciphera Pharmaceuticals INC. | $48.85 | 2025 | Qinlock, Romvimza |
| Geron Corporation | $42.13 | 2025 | Rytelo |
| Eisai INC. | $34.26 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $32.04 | 2024-2025 | Pyrukynd |
| Novocure INC. | $30.74 | 2025 | Optune Lua (Novottf-200t) |
| Azurity Pharmaceuticals, INC. | $27.42 | 2025 | Danziten, Vivimusta |
| Abbvie INC. | $27.26 | 2024 | |
| Alnylam Pharmaceuticals INC. | $26.18 | 2025 | Givlaari |
| Corcept Therapeutics | $25.26 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $23.61 | 2025 | Ojjaara |
| Alexion Pharmaceuticals, INC. | $23.20 | 2024 | Ultomiris |
| Genmab U.S., INC. | $22.54 | 2025 | Epkinly |
| Novo Nordisk INC | $22.21 | 2025 | |
| Aveo Pharmaceuticals, INC. | $21.83 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.86 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $18.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.16 | 2025 | Opdivo |
| Rigel Pharmaceuticals, INC. | $17.35 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Caris Mpi, INC. | $16.33 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $14.81 | 2025 | Verzenio, Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.